Evaro Raises $1.5M Seed Funding for AI-Powered Healthcare
Dr. Thuria Wenbar and Dr. Oskar Wendowski founded Evaro, a digital health startup based in London, UK. The company specializes in providing AI-powered clinical and drug prescription services for minor health conditions. Recently, they secured $1.5M in Seed funding in a round led by Cornerstone VC and Exceptional Ventures. Other participants in the round include Catalisi’s investment arm, Syndicate Room, and the University of East Anglia.
The funding will fuel Evaro's expansion in the B2B market, as they plan to offer a plug-and-play product that consumer brands can use to provide managed medication prescription services to their customers.
With the new funds, Evaro aims to increase its medication catalogue from 200 to 2,000 treatments, covering 70% of minor health issues commonly addressed by NHS doctors. Additionally, the company intends to obtain its Care Quality Commission (CQC) license, allowing for more comprehensive patient care, including diagnosis and therapy initiation.
Evaro utilizes an artificial intelligence and machine learning model trained on 13.5 million patient records. This advanced technology enables the company to offer AI-driven asynchronous consultations and private prescription medication. To prioritize patient safety, Evaro follows a strict regulatory-compliant process. Online treatment requests require an asynchronous consultation, and measures are in place to detect answer manipulation. Furthermore, all drug orders undergo scrutiny to ensure safe dosages and quantities, with GP notifications triggered when necessary.
They've invested in Evaro
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK